GB9613470D0 - Small solid oral dosage form - Google Patents

Small solid oral dosage form

Info

Publication number
GB9613470D0
GB9613470D0 GBGB9613470.5A GB9613470A GB9613470D0 GB 9613470 D0 GB9613470 D0 GB 9613470D0 GB 9613470 A GB9613470 A GB 9613470A GB 9613470 D0 GB9613470 D0 GB 9613470D0
Authority
GB
United Kingdom
Prior art keywords
dosage form
oral dosage
solid oral
small solid
small
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9613470.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB9613470(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Priority to GBGB9613470.5A priority Critical patent/GB9613470D0/en
Publication of GB9613470D0 publication Critical patent/GB9613470D0/en
Priority to MYPI20041863A priority patent/MY146868A/en
Priority to MYPI20093392A priority patent/MY156312A/en
Priority to MYPI97002679A priority patent/MY123149A/en
Priority to DE69730834T priority patent/DE69730834T2/de
Priority to IL12756497A priority patent/IL127564A0/xx
Priority to DE69738089T priority patent/DE69738089T2/de
Priority to AT97929209T priority patent/ATE276750T1/de
Priority to CN031466788A priority patent/CN1475207B/zh
Priority to PL97330709A priority patent/PL188233B1/pl
Priority to KR1020097017936A priority patent/KR101161283B1/ko
Priority to EP03027840A priority patent/EP1410797B1/en
Priority to AT06126819T priority patent/ATE446749T1/de
Priority to EP06126838A priority patent/EP1767207A3/en
Priority to DE69739642T priority patent/DE69739642D1/de
Priority to PCT/EP1997/003172 priority patent/WO1997049394A2/en
Priority to BR9709956A priority patent/BR9709956A/pt
Priority to JP10502269A priority patent/JP2000506540A/ja
Priority to NZ333385A priority patent/NZ333385A/xx
Priority to DK03027840T priority patent/DK1410797T3/da
Priority to CA2673462A priority patent/CA2673462C/en
Priority to KR1020087000538A priority patent/KR20080014149A/ko
Priority to PL97363524A priority patent/PL188271B1/pl
Priority to US09/202,805 priority patent/US6294197B1/en
Priority to PT06126819T priority patent/PT1767206E/pt
Priority to SI9730686T priority patent/SI0914119T1/xx
Priority to EP06126819A priority patent/EP1767206B1/en
Priority to CNB971958912A priority patent/CN1133427C/zh
Priority to PT97929209T priority patent/PT914119E/pt
Priority to SK1784-98A priority patent/SK285902B6/sk
Priority to HU0203374A priority patent/HU229134B1/hu
Priority to CA002259148A priority patent/CA2259148C/en
Priority to TR1998/02698T priority patent/TR199802698T2/xx
Priority to RU99101056/63D priority patent/RU2294743C2/ru
Priority to AU33402/97A priority patent/AU724998C/en
Priority to KR1020057015071A priority patent/KR100792389B1/ko
Priority to CZ0426998A priority patent/CZ296850B6/cs
Priority to KR1020067011260A priority patent/KR20060079260A/ko
Priority to EP97929209A priority patent/EP0914119B1/en
Priority to ES06126819T priority patent/ES2335683T3/es
Priority to EP06126834A priority patent/EP1776953A1/en
Priority to HK99105148.2A priority patent/HK1019858B/en
Priority to KR1020117011286A priority patent/KR101208430B1/ko
Priority to DK06126819.9T priority patent/DK1767206T3/da
Priority to ES03027840T priority patent/ES2290400T3/es
Priority to EP06126829A priority patent/EP1774967A1/en
Priority to DK97929209T priority patent/DK0914119T3/da
Priority to KR1019980710521A priority patent/KR100618038B1/ko
Priority to CN2006100999105A priority patent/CN1951372B/zh
Priority to ES97929209T priority patent/ES2231873T3/es
Priority to RU99101056/14A priority patent/RU2203054C2/ru
Priority to SI9730773T priority patent/SI1410797T1/sl
Priority to EP09001681A priority patent/EP2055301A1/en
Priority to PT03027840T priority patent/PT1410797E/pt
Priority to AT03027840T priority patent/ATE371449T1/de
Priority to CO97034775A priority patent/CO4870755A1/es
Priority to PE1997000539A priority patent/PE87498A1/es
Priority to ARP970102790A priority patent/AR008618A1/es
Priority to IDP972207A priority patent/ID17553A/id
Priority to ZA9705673A priority patent/ZA975673B/xx
Priority to TW086113018A priority patent/TW473394B/zh
Priority to NO19986056A priority patent/NO317181B1/no
Priority to US09/920,159 priority patent/US6485745B1/en
Priority to US10/251,009 priority patent/US6858228B2/en
Priority to JP2003014987A priority patent/JP2003231634A/ja
Priority to NZ524346A priority patent/NZ524346A/en
Priority to NO20041287A priority patent/NO331739B1/no
Priority to HK04103718.1A priority patent/HK1060700B/xx
Priority to CY0600007A priority patent/CY2553B1/xx
Priority to RU2007100200/15A priority patent/RU2453306C2/ru
Priority to ARP070100474A priority patent/AR059324A2/es
Priority to JP2007170267A priority patent/JP4969338B2/ja
Priority to IL195339A priority patent/IL195339A0/en
Priority to RU2009115778/15A priority patent/RU2009115778A/ru
Priority to JP2011270429A priority patent/JP2012051948A/ja
Priority to RU2013113610/15A priority patent/RU2013113610A/ru
Priority to JP2013221985A priority patent/JP2014012747A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB9613470.5A 1996-06-27 1996-06-27 Small solid oral dosage form Pending GB9613470D0 (en)

Priority Applications (77)

Application Number Priority Date Filing Date Title
GBGB9613470.5A GB9613470D0 (en) 1996-06-27 1996-06-27 Small solid oral dosage form
MYPI20041863A MY146868A (en) 1996-06-27 1997-06-14 Solid oral dosage forms of valsartan
MYPI20093392A MY156312A (en) 1996-06-27 1997-06-14 Solid oral dosage forms of valsartan
MYPI97002679A MY123149A (en) 1996-06-27 1997-06-14 Solid oral dosage forms of valsartan
DE69730834T DE69730834T2 (de) 1996-06-27 1997-06-18 Verfahren zur herstellung von festen oralen dosierungsformen von valsartan
IL12756497A IL127564A0 (en) 1996-06-27 1997-06-18 Solid oral dosage forms of valsartan
DE69738089T DE69738089T2 (de) 1996-06-27 1997-06-18 Feste orale Dosierungsformen enthaltend Valsartan
AT97929209T ATE276750T1 (de) 1996-06-27 1997-06-18 Verfahren zur herstellung von festen oralen dosierungsformen von valsartan
CN031466788A CN1475207B (zh) 1996-06-27 1997-06-18 含瓦尔沙登和氢氯噻嗪的固体口服剂量形式
PL97330709A PL188233B1 (pl) 1996-06-27 1997-06-18 Sposób formowania sprasowanej stałej, doustnej postaci dawkowania valsartanu
KR1020097017936A KR101161283B1 (ko) 1996-06-27 1997-06-18 발사르탄의 고형 경구제형
EP03027840A EP1410797B1 (en) 1996-06-27 1997-06-18 Solid oral dosage forms comprising valsartan
AT06126819T ATE446749T1 (de) 1996-06-27 1997-06-18 Feste orale dosierungsformen enthaltend valsartan und hydrochlorothiazide
EP06126838A EP1767207A3 (en) 1996-06-27 1997-06-18 Solid oral dosage forms comprising valsartan
DE69739642T DE69739642D1 (de) 1996-06-27 1997-06-18 Feste orale Dosierungsformen enthaltend Valsartan und Hydrochlorothiazide
PCT/EP1997/003172 WO1997049394A2 (en) 1996-06-27 1997-06-18 Sold oral dosage forms of valsartan
BR9709956A BR9709956A (pt) 1996-06-27 1997-06-18 Formas de dosagem oral sólidas de valsartan
JP10502269A JP2000506540A (ja) 1996-06-27 1997-06-18 バルサルタンの固体経口剤形
NZ333385A NZ333385A (en) 1996-06-27 1997-06-18 Solid oral dosage forms containing 35% of valsartan
DK03027840T DK1410797T3 (da) 1996-06-27 1997-06-18 Faste orale dosisformer indeholdende valsartan
CA2673462A CA2673462C (en) 1996-06-27 1997-06-18 Solid oral dosage forms of valsartan
KR1020087000538A KR20080014149A (ko) 1996-06-27 1997-06-18 발사르탄의 고형 경구제형
PL97363524A PL188271B1 (pl) 1996-06-27 1997-06-18 Sprasowana, stała, doustna postać dawkowania valsartanu
US09/202,805 US6294197B1 (en) 1996-06-27 1997-06-18 Solid oral dosage forms of valsartan
PT06126819T PT1767206E (pt) 1996-06-27 1997-06-18 Formas de dosagem orais sólidas compreendendo valsartan e hidroclorotiazida
SI9730686T SI0914119T1 (en) 1996-06-27 1997-06-18 Process for forming solid oral dosage forms of valsartan
EP06126819A EP1767206B1 (en) 1996-06-27 1997-06-18 Solid oral dosage forms comprising valsartan and hydrochlorothiazide
CNB971958912A CN1133427C (zh) 1996-06-27 1997-06-18 瓦尔沙登的固体口服剂量形式
PT97929209T PT914119E (pt) 1996-06-27 1997-06-18 Processo para a formacao de formas de dosagem oral solidas de valsartan
SK1784-98A SK285902B6 (sk) 1996-06-27 1997-06-18 Spôsob prípravy komprimovanej pevnej perorálnej liekovej formy valsartanu
HU0203374A HU229134B1 (en) 1996-06-27 1997-06-18 Process of forming a compressed solid oral dosage form comprising valsartan
CA002259148A CA2259148C (en) 1996-06-27 1997-06-18 Solid oral dosage forms of valsartan
TR1998/02698T TR199802698T2 (xx) 1996-06-27 1997-06-18 Valsartan�n kat� oral doz formlar�.
RU99101056/63D RU2294743C2 (ru) 1996-06-27 1997-06-18 Твердые оральные дозирумые формы на основе вальсартана
AU33402/97A AU724998C (en) 1996-06-27 1997-06-18 Solid oral dosage forms of valsartan
KR1020057015071A KR100792389B1 (ko) 1996-06-27 1997-06-18 발사르탄의 고형 경구제형
CZ0426998A CZ296850B6 (cs) 1996-06-27 1997-06-18 Zpusob prípravy pevné stlacené orální dávkové formy valsartanu a taková dávková forma
KR1020067011260A KR20060079260A (ko) 1996-06-27 1997-06-18 발사르탄의 고형 경구제형
EP97929209A EP0914119B1 (en) 1996-06-27 1997-06-18 Process for forming solid oral dosage forms of valsartan
ES06126819T ES2335683T3 (es) 1996-06-27 1997-06-18 Formas de dosificacion oral solidas que comprenden valsartan e hidroclorotiazida.
EP06126834A EP1776953A1 (en) 1996-06-27 1997-06-18 Solid oral dosage forms comprising valsartan
HK99105148.2A HK1019858B (en) 1996-06-27 1997-06-18 Process for forming solid oral dosage forms of valsartan
KR1020117011286A KR101208430B1 (ko) 1996-06-27 1997-06-18 발사르탄의 고형 경구제형
DK06126819.9T DK1767206T3 (da) 1996-06-27 1997-06-18 Faste orale doseringsformer indeholdende valsartan og hydrochlorhiazid
ES03027840T ES2290400T3 (es) 1996-06-27 1997-06-18 Formas de dosificacion oral solidas que comprenden valsartan.
EP06126829A EP1774967A1 (en) 1996-06-27 1997-06-18 Solid oral dosage forms comprising valsartan
DK97929209T DK0914119T3 (da) 1996-06-27 1997-06-18 Fremgangsmåde til fremstilling af faste orale dosisformer af valsartan
KR1019980710521A KR100618038B1 (ko) 1996-06-27 1997-06-18 발사르탄의고형경구제형
CN2006100999105A CN1951372B (zh) 1996-06-27 1997-06-18 含瓦尔沙登和氢氯噻嗪的固体口服剂量形式
ES97929209T ES2231873T3 (es) 1996-06-27 1997-06-18 Procedimiento de preparacion de formas solidas de valsartan para dosificacion oral.
RU99101056/14A RU2203054C2 (ru) 1996-06-27 1997-06-18 Твердые оральные дозирумые формы на основе вальсартана
SI9730773T SI1410797T1 (sl) 1996-06-27 1997-06-18 Trdne farmacevtske oblike za peroralno uporabo, ki vključujejo valsartan
EP09001681A EP2055301A1 (en) 1996-06-27 1997-06-18 Solid oral dosage forms comprising valsartan
PT03027840T PT1410797E (pt) 1996-06-27 1997-06-18 Formas de dosagem oral sólidas que contêm valsartan
AT03027840T ATE371449T1 (de) 1996-06-27 1997-06-18 Feste orale dosierungsformen enthaltend valsartan
CO97034775A CO4870755A1 (es) 1996-06-27 1997-06-23 Formas solidas de dosificacion oral, procedimiento para fa- bricarlas, "coprimates", granulados.
PE1997000539A PE87498A1 (es) 1996-06-27 1997-06-24 Formas solidas de dosificacion oral
ARP970102790A AR008618A1 (es) 1996-06-27 1997-06-25 PROCEDIMENTO PARA LA PREPARACIoN DE UNA FORMA SoLIDA COMPRIMIDA DE DOSIFICACIoN ORAL Y PROCEDIMIENTO PARA LA PREPARACIoN DE UN MATERIAL COMPACTADO DE GRANULACIoN GRUESA SIN COHESIoN ADECUADO PARA MÉTODOS ULTERIORES DE MOLIENDA Y COMPRESIoN ("COPRIMATE").
IDP972207A ID17553A (id) 1996-06-27 1997-06-26 Bentuk-bentuk padatan dosis oral
ZA9705673A ZA975673B (en) 1996-06-27 1997-06-26 Solid oral dosage forms.
TW086113018A TW473394B (en) 1996-06-27 1997-09-09 Pharmaceutical composition comprising a smaller oral dosage form of valsartan
NO19986056A NO317181B1 (no) 1996-06-27 1998-12-22 Faste orale doseringsformer av valsartan
US09/920,159 US6485745B1 (en) 1996-06-27 2001-08-01 Solid oral dosage forms of valsartan
US10/251,009 US6858228B2 (en) 1996-06-27 2002-09-20 Solid oral dosage forms of valsartan
JP2003014987A JP2003231634A (ja) 1996-06-27 2003-01-23 バルサルタンの固体経口剤形
NZ524346A NZ524346A (en) 1996-06-27 2003-02-21 Solid oral dosage forms of valsartan
NO20041287A NO331739B1 (no) 1996-06-27 2004-03-26 Komprimerte, faste orale doseringsformer av valsartan og hydroklortiazid
HK04103718.1A HK1060700B (en) 1996-06-27 2004-05-25 Solid oral dosage forms of valsartan
CY0600007A CY2553B1 (en) 1996-06-27 2006-03-21 Solid oral dosage forms of valsartan
RU2007100200/15A RU2453306C2 (ru) 1996-06-27 2007-01-10 Твердые оральные дозируемые формы на основе вальсартана
ARP070100474A AR059324A2 (es) 1996-06-27 2007-02-06 Una forma solida de dosificacion oral
JP2007170267A JP4969338B2 (ja) 1996-06-27 2007-06-28 バルサルタンの固体経口剤形
IL195339A IL195339A0 (en) 1996-06-27 2008-11-17 Solid oral dosage forms of valsartan
RU2009115778/15A RU2009115778A (ru) 1996-06-27 2009-04-27 Твердые оральные дозируемые формы на основе вальсартана
JP2011270429A JP2012051948A (ja) 1996-06-27 2011-12-09 バルサルタンの固体経口剤形
RU2013113610/15A RU2013113610A (ru) 1996-06-27 2013-03-26 Твердые оральные дозируемые формы на основе вальсартана
JP2013221985A JP2014012747A (ja) 1996-06-27 2013-10-25 バルサルタンの固体経口剤形

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9613470.5A GB9613470D0 (en) 1996-06-27 1996-06-27 Small solid oral dosage form

Publications (1)

Publication Number Publication Date
GB9613470D0 true GB9613470D0 (en) 1996-08-28

Family

ID=10795969

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9613470.5A Pending GB9613470D0 (en) 1996-06-27 1996-06-27 Small solid oral dosage form

Country Status (32)

Country Link
US (3) US6294197B1 (enExample)
EP (7) EP2055301A1 (enExample)
JP (5) JP2000506540A (enExample)
KR (6) KR100618038B1 (enExample)
CN (3) CN1951372B (enExample)
AR (2) AR008618A1 (enExample)
AT (3) ATE371449T1 (enExample)
BR (1) BR9709956A (enExample)
CA (2) CA2673462C (enExample)
CO (1) CO4870755A1 (enExample)
CY (1) CY2553B1 (enExample)
CZ (1) CZ296850B6 (enExample)
DE (3) DE69738089T2 (enExample)
DK (3) DK0914119T3 (enExample)
ES (3) ES2290400T3 (enExample)
GB (1) GB9613470D0 (enExample)
HU (1) HU229134B1 (enExample)
ID (1) ID17553A (enExample)
IL (2) IL127564A0 (enExample)
MY (3) MY123149A (enExample)
NO (2) NO317181B1 (enExample)
NZ (2) NZ333385A (enExample)
PE (1) PE87498A1 (enExample)
PL (2) PL188233B1 (enExample)
PT (3) PT1767206E (enExample)
RU (5) RU2294743C2 (enExample)
SI (2) SI0914119T1 (enExample)
SK (1) SK285902B6 (enExample)
TR (1) TR199802698T2 (enExample)
TW (1) TW473394B (enExample)
WO (1) WO1997049394A2 (enExample)
ZA (1) ZA975673B (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US20030045561A1 (en) * 2001-02-06 2003-03-06 Smithkline Beecham Corporation Method of treating isolated systolic hypertension
ZA991706B (en) * 1998-03-04 2000-10-03 Takeda Chemical Industries Ltd Sustained-release preparation for Aii Antagonist, production and use thereof.
WO1999059544A2 (en) 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
DK1096932T3 (da) * 1998-07-10 2007-10-15 Novartis Pharma Ag Antihypertensiv kombination af valsartan og calciumkanalblokker
DK1588706T3 (da) 1998-12-23 2012-01-16 Novartis Ag Valsartantablet
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
NZ513039A (en) * 1999-01-26 2003-11-28 Novartis Ag Use of angiotensin II receptor antagonists for treating acute myocardial infarction
AU783855B2 (en) * 1999-08-24 2005-12-15 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
DE10066408B4 (de) * 2000-03-24 2010-03-18 3M Espe Dental Ag Verwendung feinkörniger Pulver für supragingivales Pulverstrahlen
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
AU2005200815B2 (en) * 2000-06-22 2008-01-17 Novartis Ag Solid valsartan pharmaceutical compositions
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
HUP0301390A3 (en) * 2000-06-22 2005-04-28 Novartis Ag Oral pharmaceutical composition containing valsartan
US20030207930A1 (en) 2000-07-19 2003-11-06 Erwin Marti Valsartan salts
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US7199144B2 (en) * 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
US20040242661A1 (en) * 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
EP1556363A2 (en) * 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Process for the preparation of valsartan and intermediates thereof
TW200505879A (en) * 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
WO2005013964A1 (ja) 2003-08-08 2005-02-17 Ajinomoto Co., Inc. ナテグリニド含有製剤
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
PL382044A1 (pl) * 2003-11-03 2007-08-06 Zentiva, A.S. Preparat zawierający walsartan
JP2005187793A (ja) * 2003-12-24 2005-07-14 Rohm & Haas Electronic Materials Llc 改良された接着剤
WO2005082329A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
CN1993355A (zh) 2004-09-02 2007-07-04 特瓦制药工业有限公司 奥美沙坦酯的纯化方法
DE14172396T1 (de) * 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
US20080050605A1 (en) * 2004-10-15 2008-02-28 Rapp Knut M Pan Coating Process
DK2033629T3 (da) * 2004-12-24 2013-02-04 Krka Fast farmaceutisk sammensætning omfattende valsartan
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
CA2610694A1 (en) * 2005-05-31 2006-12-07 Mylan Laboratories, Inc. Compositions comrising nebivolol
EP1812411A2 (en) * 2005-07-05 2007-08-01 Teva Pharmaceutical Industries Ltd. Process for preparing valsartan
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
WO2007052307A2 (en) * 2005-10-31 2007-05-10 Lupin Limited Stable solid oral dosage forms of valsartan
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
CA2654408C (en) 2006-06-06 2018-05-08 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
JP2010508266A (ja) * 2006-10-30 2010-03-18 ハナル ファーマシューティカル カンパニー リミテッド チアジド系化合物およびアンジオテンシン−ｉｉ−受容体遮断剤を含む放出性が制御された薬学的組成物
WO2008064338A2 (en) * 2006-11-22 2008-05-29 Rubicon Research Pvt. Ltd. Valsartan formulation for pulsatile delivery
EP2139473A1 (en) * 2007-03-29 2010-01-06 Alembic Limited Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
CA2694516A1 (en) * 2007-07-31 2009-02-05 Cargill, Incorporated Direct compressible dextrose
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
AR066168A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Formulaciones galenicas de compuestos organicos
CN101888829A (zh) * 2007-10-09 2010-11-17 诺瓦提斯公司 缬沙坦的药物制剂
WO2009061713A1 (en) 2007-11-06 2009-05-14 Novartis Ag Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
MX2010007281A (es) * 2007-12-31 2010-10-05 Lupin Ltd Composiciones farmaceuticas de amlodipina y valsartan.
BRPI0907151A2 (pt) * 2008-02-28 2015-07-07 Novartis Ag Formas sólidas de dosagem oral de valsartan e métodos de produzir essas formilações
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
US20090226516A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Sartan compositions
EP2281557A4 (en) * 2008-04-29 2011-08-31 Hanall Biopharma Co Ltd PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
WO2009149493A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
KR101033975B1 (ko) * 2008-10-10 2011-05-11 이희엽 직접압축법을 이용한 발사르탄 함유 고형 경구 제형의 제조방법 및 이에 따라 제조된 고형 경구 제형
DE102008051783A1 (de) * 2008-10-17 2010-04-22 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Valsartan enthaltende Tablette
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
WO2010104485A2 (en) 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
RU2398570C1 (ru) * 2009-04-17 2010-09-10 Илья Николаевич Медведев Способ снижения содержания микровезикул в крови при стабильной стенокардии напряжения i-ii функционального класса с артериальной гипертонией
KR101084783B1 (ko) * 2009-09-01 2011-11-22 삼성에스디아이 주식회사 이차 전지 및 그의 제조 방법
WO2011027021A1 (en) * 2009-09-01 2011-03-10 Orion Corporation A method for the treatment of hypertension
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CN101897675B (zh) * 2010-02-10 2012-11-21 温士顿医药股份有限公司 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
JP5882796B2 (ja) 2011-03-31 2016-03-09 キヤノン株式会社 振動体の駆動方法、振動装置、該振動装置を有する駆動装置、及び光学機器
GB201116993D0 (en) * 2011-10-03 2011-11-16 Ems Sa Pharmaceutical compositions of antihypertensives
EP2797580A2 (en) 2011-12-26 2014-11-05 Novartis AG Tablets and dry-coated agents
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
WO2014038895A1 (ko) * 2012-09-06 2014-03-13 한국콜마주식회사 발사르탄 함유 고형 경구제형 및 그 제조방법
JP2014062064A (ja) * 2012-09-21 2014-04-10 Ohara Yakuhin Kogyo Kk バルサルタン含有錠剤の製造方法
JP6238831B2 (ja) * 2014-04-25 2017-11-29 沢井製薬株式会社 バルサルタン含有錠剤及びその製造方法
JP6141472B2 (ja) * 2016-03-02 2017-06-07 大原薬品工業株式会社 バルサルタン含有錠剤の製造方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CA3103599A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200039A (en) 1962-05-28 1965-08-10 Pfizer & Co C Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu
GB1422176A (en) 1973-05-05 1976-01-21 Beecham Group Ltd Pharmaceutical tablets
AU528098B2 (en) 1978-11-16 1983-04-14 Beecham Group Plc Analgesic tablet
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4238485A (en) * 1979-10-29 1980-12-09 Merck & Co., Inc. Novel pharmaceutical compositions
EP0070127A3 (en) 1981-07-10 1983-08-17 Beecham Group Plc Tablets
US4543359A (en) * 1982-10-01 1985-09-24 Eaton Laboratories, Inc. Treating cardiac arrhythmias with dantrolene sodium
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4743612A (en) * 1986-10-17 1988-05-10 Berlex Laboratories, Inc. Prodrug derivatives of the cardiotonic agent 4-ethyl-1,3-dihydro-5-(4-(2-methyl-1H-imidazol-1-yl)benzoyl)-2H-imidazol-2-one, composition containing them, and method of using them to treat cardiac failure
DE3705055A1 (de) * 1987-02-18 1988-09-01 Boehringer Ingelheim Kg Verwendung von 2-(3-fluor-4-methylphenylimino)-imidazolidin zur behandlung der koronaren herzkrankheit
JP2518854B2 (ja) * 1987-06-19 1996-07-31 旭化成工業株式会社 固形製剤の製法
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
SE506179C2 (sv) 1989-01-23 1997-11-17 Ciba Geigy Ag Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
IL97219A (en) * 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
EP0550689A1 (en) * 1990-09-28 1993-07-14 Merck & Co. Inc. Ibuprofen-diuretic combinations
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
IL104755A0 (en) 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
WO1994009778A1 (en) 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
EP0676967A4 (en) 1992-12-30 1996-10-02 Fmc Corp RELEASED, EXTENDED, EASY TO PRODUCE EXCIPIENT, BASED ON KONJAC GLUCOMANNANE.
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5464854A (en) 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
AT401871B (de) * 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
JP3534130B2 (ja) * 1994-03-01 2004-06-07 旭化成ケミカルズ株式会社 医薬品組成物
GB9404010D0 (en) * 1994-03-02 1994-04-20 Opt Tel Services Limited Telephone dialling monitoring and route selecting apparatus
JPH09510225A (ja) * 1994-03-17 1997-10-14 チバ−ガイギー アクチェンゲゼルシャフト バルサルタンを用いる糖尿病性ネフロパシーの治療
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE19502065C2 (de) * 1995-01-14 1996-05-02 Prophyta Biolog Pflanzenschutz Pilzisolat mit fungizider Wirkung
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
JP2011123241A (ja) * 2009-12-10 2011-06-23 Canon Inc 撮影システム

Also Published As

Publication number Publication date
MY146868A (en) 2012-09-28
EP1776953A1 (en) 2007-04-25
EP1410797A1 (en) 2004-04-21
CN1133427C (zh) 2004-01-07
KR20050092054A (ko) 2005-09-16
JP2012051948A (ja) 2012-03-15
JP2014012747A (ja) 2014-01-23
US20030035832A1 (en) 2003-02-20
AU724998B2 (en) 2000-10-05
MY123149A (en) 2006-05-31
HUP0203374A3 (en) 2004-06-28
EP1410797B1 (en) 2007-08-29
EP0914119A2 (en) 1999-05-12
US6294197B1 (en) 2001-09-25
CN1951372A (zh) 2007-04-25
WO1997049394A2 (en) 1997-12-31
PT1767206E (pt) 2010-01-27
RU2203054C2 (ru) 2003-04-27
BR9709956A (pt) 1999-08-10
CA2673462C (en) 2011-10-04
ES2290400T3 (es) 2008-02-16
DE69738089D1 (de) 2007-10-11
KR20090099020A (ko) 2009-09-18
KR100792389B1 (ko) 2008-01-08
CA2259148A1 (en) 1997-12-31
ATE276750T1 (de) 2004-10-15
KR20000022111A (ko) 2000-04-25
PT1410797E (pt) 2007-12-03
EP1767207A2 (en) 2007-03-28
DE69730834D1 (de) 2004-10-28
NO317181B1 (no) 2004-09-06
IL127564A0 (en) 1999-10-28
CZ426998A3 (cs) 1999-03-17
CN1951372B (zh) 2011-03-23
AR008618A1 (es) 2000-02-09
HUP0203374A2 (hu) 2004-05-28
NO20041287L (no) 2004-03-26
NO986056L (no) 1998-12-22
PE87498A1 (es) 1998-12-21
TR199802698T2 (xx) 1999-04-21
IL195339A0 (en) 2009-08-03
HU229134B1 (en) 2013-08-28
DE69738089T2 (de) 2008-05-21
PL188233B1 (pl) 2004-12-31
EP2055301A1 (en) 2009-05-06
JP2007238637A (ja) 2007-09-20
ATE446749T1 (de) 2009-11-15
RU2009115778A (ru) 2010-11-10
RU2013113610A (ru) 2014-10-10
SK285902B6 (sk) 2007-10-04
JP2000506540A (ja) 2000-05-30
DE69730834T2 (de) 2005-10-06
DK0914119T3 (da) 2005-01-31
TW473394B (en) 2002-01-21
KR20080014149A (ko) 2008-02-13
SI1410797T1 (sl) 2008-08-31
US6858228B2 (en) 2005-02-22
EP0914119A3 (en) 2002-03-06
PL188271B1 (pl) 2005-01-31
CN1475207B (zh) 2010-09-29
HK1019858A1 (en) 2000-06-09
CA2673462A1 (en) 1997-12-31
KR101208430B1 (ko) 2012-12-05
EP1767206A3 (en) 2007-04-18
RU2294743C2 (ru) 2007-03-10
JP2003231634A (ja) 2003-08-19
PL330709A1 (en) 1999-05-24
ZA975673B (en) 1997-12-29
RU2453306C2 (ru) 2012-06-20
EP1767206A2 (en) 2007-03-28
KR101161283B1 (ko) 2012-07-02
ES2231873T3 (es) 2005-05-16
JP4969338B2 (ja) 2012-07-04
CO4870755A1 (es) 1999-12-27
EP1767207A3 (en) 2007-04-18
SK178498A3 (en) 1999-06-11
NO986056D0 (no) 1998-12-22
DE69739642D1 (de) 2009-12-10
CA2259148C (en) 2009-09-29
WO1997049394A3 (en) 2001-12-20
NZ333385A (en) 2000-09-29
CZ296850B6 (cs) 2006-07-12
RU2007100200A (ru) 2008-07-20
NZ524346A (en) 2004-09-24
CN1475207A (zh) 2004-02-18
EP0914119B1 (en) 2004-09-22
MY156312A (en) 2016-01-29
KR100618038B1 (ko) 2006-11-30
AU3340297A (en) 1998-01-14
ES2335683T3 (es) 2010-03-31
DK1767206T3 (da) 2010-01-25
AR059324A2 (es) 2008-03-26
EP1774967A1 (en) 2007-04-18
CN1232394A (zh) 1999-10-20
HK1060700A1 (en) 2004-08-20
SI0914119T1 (en) 2005-04-30
US6485745B1 (en) 2002-11-26
ATE371449T1 (de) 2007-09-15
KR20110063587A (ko) 2011-06-10
DK1410797T3 (da) 2007-10-15
PT914119E (pt) 2005-02-28
ID17553A (id) 1998-01-08
EP1767206B1 (en) 2009-10-28
CY2553B1 (en) 2008-07-02
NO331739B1 (no) 2012-03-12
KR20060079260A (ko) 2006-07-05

Similar Documents

Publication Publication Date Title
GB9613470D0 (en) Small solid oral dosage form
EP1020193A4 (en) ORAL PREPARATION
GB9801363D0 (en) Novel dosage form
HUP9903407A3 (en) Oral pharmaceutical preparation containing ibandronat
ZA987551B (en) Solid pharmaceutical dosage forms
EP0943327A4 (en) DRUG
EG24118A (en) Pharmaceutical compositions
GB9715972D0 (en) Oral compositions
IL138192A0 (en) Controlled release oral dosage forms
EP0978288A4 (en) DRUG COMPOSITION
GB9616672D0 (en) Pharmaceutical compositions
ZA976189B (en) Oral pharmaceutical combinations
GB9610359D0 (en) Pharmaceutical compositions
HU9500618D0 (en) Oral pharmaceutical compositions
PL338922A1 (en) Oral compositions
HUP9904345A3 (en) Oral contraceptive
GB9622681D0 (en) Pharmaceutical compositions
GB9606429D0 (en) Pharmaceutical compositions
PL338781A1 (en) Dosage form
GB9623962D0 (en) Pharmaceutical composition
GB9613457D0 (en) Pharmaceutical compositions
GB9618964D0 (en) Oral composition
GB9618376D0 (en) Pharmaceutical compositions
ZA974125B (en) Oral pharmaceutical compositions
SG63838A1 (en) Oral composition